Background: Little is known about the involvement of B cells in venom immunotherapy (VIT). To elucidate changes in the B cell phenotype during this process, we examined the expression of several surface molecules on peripheral B cells before and during VIT. Methods: 15 venom-allergic patients with a history of systemic reactions after a wasp sting and venom-specific skin test reactivity as well as serum IgE were investigated before VIT (day 1), 1 day after reaching a maintenance dose of 100 µg (day 6) during inpatient rush VIT, and again on day 26 during continued outpatient maintenance therapy. Changes in the serum levels of total IgE, allergen-specific IgE (sIgE) and sIgG4 were measured by ELISA. Expression of several surface molecules on double-labelled B cells was studied by flow cytometry of peripheral blood mononuclear cells. Results: Levels of total IgE, sIgE and sIgG4 showed a significant increase after 26 days of VIT. On day 6, cell surface expression of HLA- II-DR, CD5, CD32 and CD54 was decreased in intensity and numbers of positive cells compared to day 1, while on day 26, expression of these molecules approached again baseline levels. Furthermore, a trend to decreased CD23 was noted on day 6. No changes were observed for CD40, CD86, CD95 and HLA-I-ABC. Conclusion: These data show that during initiation of rush VIT, B cell expression of surface molecules involved in T-B cell cooperation and antigen presentation is downmodulated. B cells may thus be additional direct or indirect targets of high-dose antigen therapy and contribute to the persistence of TH1 responses during maintenance VIT treatment.

Keywords:
Antigen presentation, B cells, B cell phenotype, Rush immunotherapy, Wasp venom allergy
1.
Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens T, Blaser K: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747–754.
2.
Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187–4194.
3.
Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131–1139.
4.
Kowalski ML, Jutel M: Mechanisms of specific immunotherapy of allergic diseases. Allergy 1998;53:485–492.
5.
Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J: Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;103:326–332.
6.
Bacharier LB, Jabara H, Geha RS: Molecular mechanisms of immunoglobulin E regulation. Int Arch Allergy Immunol 1998;115:257–269.
7.
Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY: CD21 is a ligand for CD23 and regulates IgE production. Nature 1992;358:505–507.
8.
Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Ellis J, Bonnefoy JY: CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem 1997;272:15613–15619.
9.
Katada Y, Tanaka T, Ochi H, Aitani M, Yokota A, Kikutani H, Suemara M, Kishimoto T: B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti-CD40 antibody. Eur J Immunol 1996;26:192–200.
10.
Djurup R, Malling HJ, Sondergaard I, Weeke B: The IgE and IgG subclass antibody response in patients allergic to yellow jacket venom undergoing different regimens of venom immunotherapy. J Allergy Clin Immunol 1985;76:46.
11.
Urbanek R, Kemeny DM, Richards D: Sub-class of IgG anti-bee venom antibody produced during bee venom immunotherapy and its relationship to long-term protection from bee stings and following termination of venom immunotherapy. Clin Allergy 1986;16:317.
12.
Youinou P, Jamin C, Lydyard PM: CD5 expression in human B-cell populations. Immunol Today 1999;20:312–316.
13.
Cong YZ, Rabin E, Wortis HH: Treatment of murine CD5- B cells with anti-Ig, but not LPS, induces surface CD5: Two B-cell activation pathways. Int Immunol 1991;3:467–476.
14.
Gary-Gouy H, Bruhns P, Schmitt C, Dalloul A, Daeron M, Bismuth G: The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J Biol Chem 2000;275:548–556.
15.
Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH: The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3:635–646.
16.
Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, Graber P, Aubry JP, Jeannin P, Plater-Zyberk C: Structure and functions of CD23. Int Rev Immunol 1997;16:113–128.
17.
Sen G, Bikah G, Venkataraman C, Bondada S: Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur J Immunol 1999;29:3319–3328.
18.
van de Stolpe A, van der Saag PT: Intercellular adhesion molecule-1. J Mol Med 1996;74:13–33.
19.
Wheeler DJ, Parveen S, Pollock K, Williams RJ: Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471. Immunology 1998;95:105–110.
20.
Hakansson L, Heinrich C, Rak S, Venge P: Activation of B-lymphocytes during pollen season. Effect of immunotherapy. Clin Exp Allergy 1998;28:791–798.
21.
Jung CM, Prinz JC, Rieber EP, Ring J: A reduction in allergen-induced Fc epsilon R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol 1995;95:77–87.
22.
Blaser K, Carballido J, Faith A, Crameri R, Akdis C: Determinants and mechanisms of human immune responses to bee venom phospholipase A2. Int Arch Allergy Immunol 1998;117:1–10.
23.
Secrist H, DeKruyff RH, Umetsu DT: Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081–1089.
24.
Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K: Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914–925.
25.
Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, Hamid Q, Tonnel AB: Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes. Immunology 1996;87:593.
26.
Segura JA, Assenmacher M, Irsch J, Hunzelmann N, Radbruch A: Systemic T-cell unresponsiveness during rush bee-venom immunotherapy. Allergy 1998;53:233.
27.
Akdis CA, Blaser K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy. FASEB J 1999;13:603.
28.
Bowen F, Haluskey J, Quill H: Altered CD40 ligand induction in tolerant T lymphocytes. Eur J Immunol 1995;25:2830.
29.
Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: Complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 1995;161:226.
30.
Nossal GJ: Clonal anergy of B cells: A flexible, reversible, and quantitative concept. J Exp Med 1996;183:1953–1956.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.